Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus +/- Bevacizumab in Advanced Renal Cell Carcinoma
NCT01198158Phase 3Terminated
- Sponsor
- National Cancer Institute
- Start
- Sep 2010
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in renal cell carcinoma (RCC), sponsored by National Cancer Institute. Started Sep 2010; status: terminated.
02
Drugs
bevacizumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01198158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01198158.